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Ebola virus (EBOV) is a highly pathogenic ﬁlovirus that causes hemorrhagic fever in humans and animals.
Here we provide evidence that cell–cell contact promotes infection mediated by the glycoprotein (GP) of
EBOV. Interestingly, expression of EBOV GP alone, even in the absence of retroviral Gag-Pol, is sufﬁcient
to transfer a retroviral vector encoding Tet-off from cell to cell. Cell-to-cell infection mediated by EBOV
GP is blocked by inhibitors of actin polymerization, but appears to be less sensitive to KZ52 neu-
tralization. Treatment of co-cultured cells with cathepsin B/L inhibitors, or an entry inhibitor 3.47 that
targets the receptor NPC1 for virus binding, also blocks cell-to-cell infection. Cell–cell contact also
enhances spread of rVSV bearing GP in monocytes and macrophages, the primary targets of natural EBOV
infection. Altogether, our study reveals that cell–cell contact promotes EBOV GP-mediated infection, and
provides new insight into understanding EBOV spread and viral pathogenesis.
& 2015 Elsevier Inc. All rights reserved.Introduction
Ebola virus (EBOV) belongs to the ﬁlovirus family and causes
severe hemorrhagic fever in humans and animals. The fatality
rates of the disease induced by EBOV can reach up to 90%, with
currently no effective antiviral drug or FDA-licensed vaccine
available (Feldmann and Geisbert, 2011; Hoenen and Feldmann,
2014a). A better understanding of EBOV infection, especially the
early stage of viral transmission, would facilitate the development
of novel therapeutic approaches to combat this deadly disease.
EBOV infection of a host cell is mediated by its sole glycoprotein,
known as GP. GP is synthesized as a precursor (GP0) in the endo-
plasmic reticulum, cleaved into GP1 and GP2 in the Golgi apparatus,
and eventually targeted to the plasma membrane for viral incor-
poration (Takada et al., 1997; White et al., 2008; Wool-Lewis and
Bates, 1999). During this process, EBOV GP is modiﬁed by N- and O-
linked glycosylation; the exact functions are still not well under-
stood (Dowling et al., 2007; Simmons et al., 2002). In mature vir-
ions, EBOV GP exists as a homotrimer, with each monomer com-
posed of GP1 and GP2 subunits that are linked by a disulﬁde bond
and non-covalent interactions (Jeffers et al., 2002; Lee et al., 2008).
As is the case for many class I viral fusion proteins, GP1 is respon-
sible for interacting with cellular receptors or cofactors, whereas
GP2 is directly involved in fusion of EBOV with target cell mem-
branes (Brindley et al., 2007; Gregory et al., 2011; Hood et al., 2010;Lee et al., 2008; Manicassamy et al., 2005; Wang et al., 2011;
Watanabe et al., 2000; Wool-Lewis and Bates, 1999).
The detailed molecular mechanism underlying EBOV GP-
mediated infection is currently unknown (White and Schornberg,
2012). However, much evidence has indicated that EBOV enters
host cells through macropinocytosis (Hunt et al., 2011; Nanbo et al.,
2010; Saeed et al., 2010), a process that is initiated by binding of
EBOV GP to attachment factors, such as DC-SIGN and TIM-1 (Alvarez
et al., 2002; Kondratowicz et al., 2011; Lin et al., 2003; Marzi et al.,
2006; Nanbo et al., 2010). Following the uptake of viral particles
into late endosomes and lysosomes, GP1 is cleaved by cellular
cysteine proteases, especially cathepsins B (CatB) and L (CatL),
resulting in the production of a fusion-competent intermediate
(Chandran et al., 2005; Dube et al., 2009; Schornberg et al., 2006)
that binds to the recently identiﬁed intracellular receptor, Niemann-
Pick type C1 (NPC1) (Côté et al., 2011; Kaletsky et al., 2007; Miller
et al., 2012). Studies from several groups have shown or suggested
that NPC1, low pH, and possibly mild reduction of GP are important
for EBOV GP-mediated infection (Bale et al., 2011; Brecher et al.,
2012; Gregory et al., 2011; Miller et al., 2012; Schornberg et al.,
2006).
Cell-to-cell transmission has been shown to play important
roles in the dissemination and pathogenesis of many pathogenic
viruses, including HIV and HCV (Brimacombe et al., 2011; Dale
et al., 2013; Roberts et al., 2015; Zhong et al., 2013). In this work,
we provide evidence that cell–cell contact facilitates infection
mediated by EBOV GP and this process requires cellular cathepsins
and NPC1. Our work supports the idea that cell-to-cell infection
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potential target of viral therapeutics.Results
Cell–cell contact promotes EBOV GP-mediated retroviral infection
EBOV is a BSL-4 agent; thus, in this study we employed several
systems, including retroviral pseudotypes, virus-like particlesFig. 1. EBOV GP mediates cell-to-cell infection of retroviral pseudotypes. (A) Schemati
Results. (B) Comparisons between cell-to-cell and cell-free infections mediated by EBO
measured 24 and 48 h after co-culture. “No Env” indicates the background Gluc activity d
differences in Gluc activity above the corresponding “No Env” background are indicated.
fold differences in Gluc activity above the corresponding “No Env” background are in
infection, KZ52 was added during co-culture. For cell-free infection, KZ52 was incubate
infection. The efﬁciencies of cell-to-cell or cell-free infection of EBOV GP and VSV-G wi
were calculated and plotted. (E) Effect of LAT-B on cell-to-cell infection mediated by EBO
co-culture, and Gluc activity was measured 24–48 h later. (F) Effect of CytoD on cell-to-
used during cell co-culture. Results are from at least three independent experiments. *p(VLPs), as well as rVSV that bear GP to determine cell-to-cell
infection. For the retroviral system, we co-transfected 293T cells
with the pQCXIP retroviral vector encoding a tetracycline-
controlled transcription factor (tTA, referred to as Tet-off here-
after), along with plasmids that encode EBOV GP and murine
leukemia virus (MLV) Gag-Pol. Following 24 h transfection, donor
293T cells producing pseudovirions were co-cultured with target
293FT cells stably expressing tetracycline-responsive element
(TRE)-driven Gaussia luciferase (293FT/TRE-GLuc); cell-to-cell
infection efﬁciency was assayed by measuring the GLuc activityc representation of cell-to-cell vs. cell-free infections. See details in Methods and
V GP and VSV-G. Results shown are averages of three independent experiments
erived from co-culture of 293T donor cells transfected with “Tet-off” alone. The fold
(C) Comparisons between cell-to-cell and cell-free infections in Transwell plates. The
dicated. (D) Effect of KZ52 on cell-to-cell and cell-free infections. For cell-to-cell
d with viral supernatants for 2 h at 37 °C prior to infection and maintained during
thout KZ52 were set to 100%, respectively, and relative activities at different doses
V GP or VSV-G. Two concentrations of LAT-B (i. e., 2 mM and 5 mM) were applied to
cell infection mediated by EBOV GP or VSV-G. Three concentrations of CytoD were
o0.05; ***po0.001.
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free viral infection, we cultured the same numbers of transfected
donor cells for the same period of time (24 h), and the collected
supernatants were used to infect target 293FT/TRE-GLuc cells that
had been pre-mixed with parental untransfected 293T cells; this
procedure would ensure the same numbers of cells to be used for
cell-free infection (Fig. 1A, bottom). Donor 293T cells expressing
VSV-G or no envelope served as controls for cell-to-cell and cell-
free infections.
Expression of EBOV GP in donor 293T cells led to a 130-fold
higher GLuc activity compared to the mock control (“No-Env”)
(Fig. 1B). In contrast, the cell-free infection was only 3–5-fold
above the background (Fig. 1B), thus resulting in a 40-fold dif-
ference between cell-to-cell and cell-free infections. Similarly,
the cell-to-cell infection efﬁciency mediated by VSV-G was much
more higher than the cell-free infection, i. e, 70-fold, although
VSV-G generally exhibited much higher Gluc activities than EBOV
GP in both cell-to-cell and cell-free infections (Fig. 1B). To con-
ﬁrm the greater cell-to-cell vs. cell-free infection mediated by
EBOV GP, we next applied a Transwell culture system, where cell-
to-cell infection was measured by co-culturing donor and target
cells on the bottom of the Transwell plates; the cell-free infection
was achieved by seeding the same number of donor cells on the
top and target cells on the bottom, allowing cell-free virions to
migrate through a 0.45 μM membrane. In this system, we
observed a 70-fold and 40-fold difference between cell-to-cell
and cell-free infection for EBOV and VSV, respectively (Fig. 1C).
We treated co-cultured cells with KZ52, a broadly neutralizing
antibody against EBOV, and observed that while KZ52 inhibited
cell-to-cell infection mediated by EBOV GP (Fig. 1D), its efﬁciency
was consistently lower than that of cell-free infection; speciﬁcity
was conﬁrmed by the absence of an effect of KZ52 on VSV-G
(Fig. 1D). We also treated co-cultured cells with inhibitors of actin
polymerization, such as latrunculin B (LAT-B) and cytochalasin D
(CytoD), which are known to block cell-to-cell transmission of
other viruses (Dale et al., 2013), and we found that both drugs
strongly inhibited, in a dose-dependent manner, cell-to-cell
infection mediated by EBOV GP and VSV-G (about 5–10 fold,
Fig. 1E and F). Interestingly, cell-free infection of EBOV was also
inhibited by LAT-B and CytoD, but only 2 fold; noticeably, the
effect of CytoD on cell-free infection was not dose-dependent,
suggesting possible cytotoxicity at higher doses (data not shown).
Collectively, these results revealed that cell–cell contact can pro-
mote EBOV GP-mediated infection, a phenomenon that has
recently been reported for HIV, hepatitis C virus (HCV) and inﬂu-
enza A virus (IAV) (Brimacombe et al., 2011; Catanese et al., 2013;
Dale et al., 2013; Roberts et al., 2015).
Ebola virus-like particles (VLPs) bearing GP are efﬁciently transferred
from cell to cell
We next evaluated if cell–cell contact can also promote EBOV
GP-mediated transfer of VP40 VLPs by using VP40-Blam-based
virion-fusion and VP40-GFP-based uptake assays. Upon a 2 h
co-culture, approximately 8.5% of 293FT/tdTomato target cells
exhibited beta-lactamase activity; the effect was inhibited by
KZ52, LAT-B and CytoD (Fig. 2A and B). In contrast, no beta-
lactamase activity was detected for cell-free infection performed
in parallel (Fig. 2C, second bar in “EBOV” group). Similar results
were also obtained for VSV-G, although the cell-to-cell transfer
efﬁciency was higher for VSV-G and was not inhibited by KZ52
(Fig. 2A and B). Spinoculation of the same cell-free VLP stock to
infect the same number of target cells resulted in 4.7% of fusion-
positive cells (FACS plots not shown), suggesting that the inability
to detect beta-lactamase activity in the cell-free infection withoutspinoculation was not due to a lack of cell-free virions produced
from the donor cells (Fig. 2C).
To directly measure VP40 protein transfer, we transfected 293T
donor cells with VP40-GFP in the presence or absence of GP, and
co-cultured the transfected cells with target 293FT/tdTomato cells.
Similar to the results obtained for VP40-Blam, cell-to-cell transfer
mediated by EBOV GP and VSV-G was detected after a 2 h co-
incubation and the levels increased after 6 h (Fig. 2D and E). Of
note, VP40-GFP alone ("No Env") exhibited some levels of transfer
(possibly due to lipid-mediated non-speciﬁc transfer reported for
EBOV), albeit at lower levels as compared to cells co-expressing GP
or VSV-G (Fig. 2D and E). Once again, cell–cell transfer mediated
by EBOV GP, but not by VSV-G or VP40 alone, was inhibited by
KZ52, although LAT-B and CytoD both effectively blocked cell-to-
cell transfer mediated of EBOV GP or VSV-G, but not by VP40 alone
(Fig. 2D and E).
Cell-to-cell transfer mediated by EBOV GP can occur without retro-
viral Gag-Pol
Because of its high sensitivity, we used the Tet-off-based ret-
roviral pseudotype system to interrogate the cellular and viral
determinants required for cell-to-cell transfer mediated by EBOV
GP. We ﬁrst explored if EBOV GP alone is sufﬁcient to mediate
transfer of retroviral vector encoding Tet-off in the absence of
MLV Gag-Pol, and found that, indeed, expression of EBOV GP in
293T donor cells (along with Tet-off but without MLV Gag-Pol)
consistently led to a signiﬁcant level of Gluc activity compared to
the mock Tet-off control (53 fold, compare bar 3 with bar 4;
po0.001). Notably, inclusion of MLV Gag-Pol in donor cells fur-
ther increased the Gluc activity only 2-fold (compare bar
1 with bar 3; Fig. 3A). Similarly, expression of VSV-G in the
absence of MLV Gag-Pol resulted in a marked increase in Gluc
activity, again with less than a 2-fold enhancement by Gag-Pol in
donor cells (Fig. 3A). To assess if EBOV GP-mediated transfer of
Tet-off from cell to cell is due to a direct cell–cell fusion on the
plasma membrane, we treated co-cultured cells with either
neutral or low pH; however, no apparent differences between
neutral and low pH in Gluc activity were found (Fig. 3B), nor was
syncytia formation observed (data not shown). In contrast, Gluc
activity was signiﬁcantly increased (20-fold) for VSV-G upon a
low pH pulse (Fig. 3B). To further conﬁrm that the increased Gluc
activity of EBOV GP was not due to direct cell–cell fusion on the
plasma membrane, we expressed GP in target cells and Tet-off in
donor cells; again, we observed no increase in Gluc activity
compared to mock control regardless of pH treatment (Fig. 3C).
The ability of this EBOV GP, which is tagged with a FLAG at the N-
terminus and has no mucin domain, to mediate cell-to-cell
transfer without MLV Gag-Pol was also conﬁrmed in additional
EBOV GP constructs: full length GP WT without any tag (“Native-
GP”) (Wool-Lewis and Bates, 1999), full length GP with an N-
terminal FLAG tag (“F-GP”), and mucin-deleted GP without an N-
terminal FLAG (“Δmuc-GP”) (Fig. 3D).
A previous study has shown that Tet-off is present in exosomes
or nanovesicles that can be secreted into culture media and
transferred to adjacent cells (Mangeot et al., 2011). We therefore
evaluated if the Gluc signal we detected might be due to secretion
of exosomes containing GP and Tet-off from donor cells. We
treated co-cultured cells with a chemical inhibitor of exosomal
production, i.e., GW4869 (Trajkovic et al., 2008), and we observed
that GW4869 indeed reduced the Gluc activity induced by EBOV
GP or VSV-G in a dose-dependent manner (2, 5, and 10 mM)
(Fig. 3E). Western blotting analysis showed that puriﬁed exosomes
contained an abundant level of GP as well as the common exo-
some marker CD63 (Ramakrishnaiah et al., 2013; Thery et al.,
2006) (Fig. 3F). We then treated target 293FT/Gluc cells with
Fig. 2. EBOV virus-like particles (VLPs) are efﬁciently transmitted from cell to cell. 293T donor cells expressing VP40-Blam (A–C) or VP40-GFP (D and E) in the presence or
absence of EBOV GP were co-cultured with 293FT/tdTomato target cells for different periods of time, and percentages of VP40-positive cells in target cells (red) were
determined by a Blam-based fusion assay or by quantifying GFP signals using ﬂow cytometry. (A) Cell-to-cell transfer of VP40-Blam in the presence of KZ52 or actin
polymerization inhibitors (LAT-B and CytoD) was measured by a Blam-based virion-cell fusion assay. The cleaved CCF2 signals (blue) represent fusion-positive cells; the
percentages are indicated inside the boxes. (B) Effect of KZ52, LAT-B, and CytoD on virion fusion following cell-to-cell transmission. The level of cell-to-cell infection with
DMSO (“Mock”) was set to 100% for plotting and comparison. (C) Summary of comparisons between cell-to-cell infection, cell-free infection without spinoculation, and cell-
free infection with spinoculation, which are mediated by EBOV GP or VSV-G. Note that cell-free infection with spinoculation conﬁrms the presence of virions in the
supernatants of donor cells, which shows minimal levels of cell-free infection without spinoculation. (D and E) Cell-to-cell infection of VP40-GFP and the effect of KZ52
(20 mg/ml), LAT-B (1 mM), and CytoD (1 mM) after 2 h and 6 h of co-culture. Results are averages and standard deviations of 3–5 independent experiments. In all ﬁgures,
*po0.05; **po0.01; ***po0.001.
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target 293FT/gluc cells compared to exosome puriﬁed from mock
cells not expressing GP (Fig. 3G). Taken together, these results
suggest that exosomes secreted from donor cells contributed to
the increased Gluc activity of EBOV GP (see Discussion).
Cleavage of EBOV GP by cathepsins is required for mediating cell-to-
cell transfer
We next determined if GP-mediated enhancement of cell-to-
cell transfer, even in the absence of a retroviral core, requires
some of the essential factors known to be necessary for EBOV
infection. Cleavage of EBOV GP by cathepsins B and L is required
for EBOV infection, possibly by priming conformational changes
of GP1 needed for receptor binding prior to membrane fusion(Chandran et al., 2005; Dube et al., 2009; Kaletsky et al., 2007;
Schornberg et al., 2006; Wong et al., 2010). We applied a panel
of protease inhibitors, including cathepsins B and L (referred to
as CatB and CatL hereafter), and evaluated their effects on EBOV
GP-mediated Tet-off transfer from donor cell to target cell. As
shown in Fig. 4A, the pan-spectrum protease inhibitor leu-
peptin, the pan-cysteine cathepsin inhibitor E64d, as well as the
CatB speciﬁc inhibitor CA074 all greatly inhibited Tet-off trans-
fer mediated by EBOV (po0.001). In sharp contrast, none of
these inhibitors had any effect on IAV (Fig. 4A). The reductions
in EBOV GP-mediated cell-to-cell transfer caused by E64d and
CA074 were dose dependent, with roughly comparable efﬁ-
ciencies (Fig. 4B; po0.01 or 0.001). We also treated co-cultured
cells with cathepsin L inhibitor III, which inhibited EBOV GP-
mediated but not IAV HA-mediated cell-to-cell transfer (Fig. 4C).
Fig. 3. Cell-to-cell transfer of retroviral pseudovirions occurs in the absence of MLV Gag-Pol and involves exosomes. (A) Comparisons of cell-to-cell and cell-free infections in
the presence or absence of MLV Gag-Pol. The fold differences in Gluc activity above the corresponding “No Env” background are indicated. Note that a 2-fold increase in
cell-to-cell transfer resulted from the presence of MLV Gag-Pol. (B) Low pH treatment increases cell-to-cell transfer mediated by VSV-G but not by EBOV GP. A pH 5.0 pulse
was applied after a 2 h co-culture, and Gluc activity was measured at 24 and 48 h, respectively. The fold differences in Gluc activity between neutral and low pH are
indicated. (C) Expression of EBOV GP (and Tet-off) in donor cells, but not in target cells, led to efﬁcient cell-to-cell transfer. (D) The ability of EBOV GP to mediate cell-to-cell
transfer is conﬁrmed by testing different versions of EBOV GP constructs. Δmuc-F-GP: a mucin-deleted GP with a FLAG tag at the N-terminus, which is mainly used in this
study; F-GP: a full length GP with the FLAG tag at the N-terminus; Δmuc-GP: a mucin-deleted GP without any tag; Native-GP: a full length GP without any tag. Relative cell-
to-cell transmission of EBOV GP was calculated by setting that of Δmuc-F-GP to 100%. (E) Effect of the exosome inhibitor GW4869 on cell-to-cell transfer. Different
concentrations of GW4869 were tested. (F) Western blotting reveals the presence of EBOV GP (anti-FLAG) in concentrated exosomes. CD63 serves as a marker of exosomes.
(G) Infection of 293FT/Gluc target cells with puriﬁed exosomes containing GP results in increased Gluc activity. Absolute Gluc read-outs are shown. In all ﬁgures, **po0.01;
***po0.001.
C. Miao et al. / Virology 488 (2016) 202–215206To distinguish if the effects of these protease inhibitors were on
donor cells or target cells, we treated donor cells with leupeptin
for 24 h before and during co-culture, or treated both donor and
target cells during co-culture. Treatment of donor cells alone
had no effect on Gluc activity; however, treatment of target cells
alone or in combination with donor cells signiﬁcantly decreased
Gluc activity (Fig. 4D). These results indicate that cathepsin
activity in target cells, rather than in donor cells, is crucial for
GP to mediate cell-to-cell transfer.Given that the protease activities of CatB and CatL are dependent
on the acidiﬁcation of late endosomes and lysosomes (Schornberg et
al., 2006), we next treated co-cultured cells with NH4Cl, a lysoso-
motropic agent, which neutralizes the acidic pH of late endosomes
and lysosomes and thereby blocks EBOV infection (Takada et al.,
1997). Cell-to-cell transfer mediated by EBOV GP or VSV-G was both
strongly inhibited by NH4Cl in a dose-dependent manner (po0.001)
(Fig. 4E). These results together demonstrated that pH-dependent
cathepsin activity is required for cell-to-cell transfer, a property that is
in line with cell-free EBOV entry.
Fig. 4. Cellular cathepsin activity is essential for cell-to-cell transfer of EBOV GP. (A) Effects of leupeptin, CA074, and E64d on cell-to-cell transfer of EBOV GP and IAV HA. Co-
cultured cells were treated with 50 mM leupeptin, 5 mM E64d, or 5 mM CA074 throughout the assay, and Gluc activity was measured 24–48 h after co-culture. (B and C) Effects
of different doses of E64d, CA074, or CatL III inhibitor on cell-to-cell transfer mediated by EBOV GP or IAV HA. For comparison, cell-to-cell transfer efﬁciencies of EBOV GP and
IAV HA in the absence of inhibitors are set to 100%, respectively. (D) Effects of leupeptin added to donor cell, target cells, and both on cell-to-cell transfer mediated by EBOV
GP. (E) Effects of NH4Cl on cell-to-cell transfer mediated by EBOV GP and VSV-G. Unless otherwise speciﬁed, results represent the averages7standard deviations of at least
three independent experiments. *po0.05; **po0.01; ***po0.001.
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Several cellular factors have recently been reported to function as
receptors or cofactors for EBOV, with NPC1 and TIM-1 being the most
prominent (Carette et al., 2011; Côté et al., 2011; Kondratowicz et al.,2011; Miller et al., 2012). We evaluated the possible roles of these two
cellular factors in EBOV GP-mediated infection by cell–cell contact. To
facilitate our analyses, we established target 293FT/Gluc cell lines
stably expressing full length NPC1, or the NPC1 domain C without the
cytoplasmic tail (gift of Kartik Chandran referred to as NPC1 CT
Fig. 5. Overexpression of NPC1 or TIM-1 increases cell-to-cell transfer mediated by EBOV GP. (A) Cell-to-cell transfer by EBOV GP was examined in parental 293FT/Gluc
(Mock, set to 100%) or 293FT/Gluc cells overexpressing full length NPC1 (NPC1) or the NPC1 domain C with the cytoplasmic tail truncated (NPC1 CT) at neutral or low pH.
(B) Western blotting analysis of the expression of NPC1 and NPC1 CT using anti-FLAG. β-actin served as the loading control. (C) Immunostaining of 293FT/Gluc cells
overexpressing NPC1 and NPC1 CT (tailless). Cells were permeabilized and stained with an anti-FLAG antibody, and the ﬂuorescence signal was visualized and analyzed by a
3D deconvoluted ﬂuorescence microscope (Leica). Arrows indicate ﬂuorescence signals on the cell surface. (D) Relative cell-to-cell transfer mediated by EBOV GP and IAV HA
examined in target cells stably expressing lentiviral vectors encoding NPC1 shRNA. Five stable cell lines expressing different clones of NPC1 shRNAs were tested, with clone 1
(Sigma #5428) consistently exhibiting signiﬁcant reduction in cell-to-cell transfer. The cell-to-cell transfer mediated by EBOV GP in parental 293FT/Gluc was set to 100% for
comparison. (E) Western blotting analysis of NPC1 in 293FT/Gluc cells expressing NPC1 shRNA. An anti-NPC1 antibody was used for probing NPC1 expression; β-actin served
as the loading control. (F) Effects of 3.47 on cell-to-cell transfer mediated by EBOV GP and IAV HA. Indicated concentrations of 3.47 were added to the co-culture media for
24–48 h before Gluc activity was measured. In all cases, **po0.01; ***po0.001.
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found that full-length NPC1, NPC1 CT, as well as TIM-1 all enhanced
cell-to-cell transfer mediated by EBOV GP (po0.01 or 0.001), with no
apparent differences between neutral and low pH (Fig. 5A). The
expression of these cellular proteins in target cells was conﬁrmed by
Western blotting (Fig. 5B). Immunoﬂuorescence staining revealed that
TIM-1 was predominantly expressed on the cell surface, as expected;
NPC1 CT was also detectable on the cell surface, similar to a previousFig. 6. Cell-to-cell transfer mediated by EBOV GP requires receptor-binding. (A) Compari
GP was set to 100%. (B) Relative cell-free infection of EBOV GP mutants in HTX cells. No
transfection scale in 6-well plate) and used to infect HTX; AP positive foci in HTX cells w
comparison. (C) Western blotting analysis of EBOV GP mutants using an anti-FLAG antib
surface expression of parental EBOV GP and mutants. 293T cells were transiently transf
Representative ﬂow cytometry proﬁles from one typical experiment are shown (D). Qu
(Geom) of each GP mutant was compared to that of parental GP, the latter of which
(F) Differential sensitivities of EBOV GP-mediated cell-to-cell transfer to the CatB inhibit
with CA074 was set to 100%. The p values indicate results of comparisons between D4
**po0.01; ***po0.001.report (Miller et al., 2012), but with much less ﬂuorescence intensity
than found for TIM-1 (Fig. 5C). The full length NPC1 protein was
primarily expressed in intracellular vesicles (Fig. 5C).
We next knocked down NPC1 in 293FT/Gluc target cells by
transducing cells with shRNA lentiviral vectors, and examined their
effects on cell-to-cell transfer mediated by EBOV GP. Among the
5 shRNA clones tested, one clone (clone 1, Sigma #5428) con-
sistently exhibited the strongest inhibition of cell-to-cell transfersons of cell-to-cell transfer by EBOV GP mutants. The transfer efﬁciency of parental
te that in this case, pseudovirions were generated from 293GP/LAPSN cells (normal
ere counted 72 h post-infection. The infectivity of parental GP was set to 100% for
ody. β-actin served as the loading control. (D and E) Flow cytometry analysis of the
ected with plasmids encoding EBOV GPs and stained using an anti-FLAG antibody.
antiﬁcation of the ﬂuorescence intensities of EBOV GPs (E). The geometric mean
was set to 100%. Results were summarized from three independent experiments.
or, CA074. Cell-to-cell transfer mediated by each GP mutant without being treated
7V or I584F and parental GP at each equivalent concentration of CA074. *po0.05;
C. Miao et al. / Virology 488 (2016) 202–215210mediated by EBOV GP (po0.01 or 0.001) (Fig. 5D). The level of
NPC1 expression in 293FT/Gluc target cells expressing this shRNA
clone was most reduced compared to cells expressing other shRNAs
and mock control (Fig. 5E). We also treated co-cultured cell with
3.47, a small molecule inhibitor that speciﬁcally blocks EBOV GP to
bind to NPC1, and found that it signiﬁcantly inhibited EBOV GP-
mediated cell-to-cell transfer (po0.001) in a dose-dependent
manner (Fig. 5F). Knockdown of NPC1 or treatment of cells with
3.47 showed no effect on IAV HA-mediated cell-to-cell transfer
(Fig. 5D and E). Altogether, these results demonstrate that endo-
genous NPC1 does play a role in EBOV GP-mediated cell-to-cell
transfer, consistent with its reported role in EBOV cell-free infection
(Carette et al., 2011; Côté et al., 2011; Miller et al., 2012).
The receptor-binding property of EBOV GP is critical for cell-to-cell
transfer
We further investigated the role of receptor binding in EBOV GP
mediated infection by cell-cell contact by making a series of GP
mutants in GP1—F88A, K95A, K114A, K115A and K140A—which
have been previously shown to impair the binding of EBOV GP to
putative receptors and NPC1 (Brindley et al., 2007; Dube et al.,
2009; Lee et al., 2008; Manicassamy et al., 2005; Miller et al., 2012;
Ou et al., 2010; Wang et al., 2011; Watanabe et al., 2000). We
found that all of these mutants exhibited signiﬁcantly decreased
cell-to-cell transfer efﬁciency; F88A and K95A had the most dra-
matic phenotype, showing an almost complete loss in Tet-off
transfer (po0.001) (Fig. 6A). Consistent with the cell-to-cell
transfer data, the cell-free infection of these mutants encoding
alkaline phosphatase (AP), especially F88A and K95A, was also
greatly reduced compared to the parental GP, albeit to different
extents (po0.05, 0.01 or 0.001) (Fig. 6B). Western blotting analysis
showed that all these GP mutants were expressed and processed
into GP1 and GP2 in viral producer cells, although to somewhat
different levels or efﬁciencies (Fig. 6C). While the relatively low
level of expression of F88A could have contributed to its low cell-
to-cell transmission activity, most mutants, including K95A, were
well expressed in transfected cells, including on the cell surface
(Fig. 6D and E), indicating that the reduced cell-to-cell and cell-
free infection efﬁciencies observed for most of these GP mutants
likely reﬂect their intrinsic low receptor binding and/or fusion
potential.
We next evaluated two additional GP mutants, D47A and I584F,
which have been recently shown to mediate EBOV entry in a
somewhat CatB-independent manner (Misasi et al., 2012; Wong
et al., 2010). Indeed, adding the CatB inhibitor CA074 to co-
cultured cells did not reduce cell-to-cell transfer for either
mutant, especially I584F, to the same extent as for the parental GP
at all concentrations tested (po0.01 or 0.001) (Fig. 6F). The rela-
tive insensitivity of mutants GP1 D47A and GP2 I584F to CA074 is
consistent with their relative independence from CatB-mediated
priming in membrane fusion and EBOV entry.
Co-culturing epithelial cells and macrophages promotes spread of
recombinant VSV (rVSV) bearing EBOV GP
The above data suggest that EBOV GP can efﬁciently mediate
transfer of VP40 or Tet-off from cell to cell. We next determined if
this could also occur in a replication-competent viral system,
especially in monocytes and macrophages, which are the primary
targets of EBOV infection in vivo. For this purpose, we employed a
replication-competent rVSV-GFP system that expresses EBOV GP
(rVSV-GFP-GP). We ﬁrst infected 293T donor cells with appro-
priate doses of rVSV-GFP-GP so that optimal numbers of GFP
positive (green) donor cells would be produced. We then co-
cultured these donor cells with target 293FT/Gluc cells that werepre-labeled with CMTMR, and cell-to-cell infection was measured
by gating the CMTMR-positive cells for GFP signals. In parallel, we
also determined cell-free infection by infecting the same CMTMR-
labeled target cells with rVSV-GFP-GP produced from donor cells
(see Methods for details).
After 2 h of co-culture, the infection rate of rVSV-GFP-GP, which
likely reﬂected a combination of cell-to-cell and cell-free infection,
was low (i.e., 0.86%). Infection was, however, signiﬁcantly
increased at 6 h (9.9%) and 12 h (47.1%) (Fig. 7A). In contrast, cell-
free infection of rVSV-GFP-GP was virtually undetectable before
6 h following co-culture (0.708%), and only became quite apparent
after 12 h (4.58%); this was 10-fold lower than infection via cell-
cell contact. By treating the co-cultured cells with KZ52, LAT-B, or
CytoD, as we had done for retroviral pseudoviral and VLP systems,
we observed that rVSV-GFP-GP infection via cell–cell contact was
strongly inhibited by all three agents (Fig. 7B). Of note, cell-free
infection of rVSV-GFP-GP was also affected by LAT-B and Cyto-D,
consistent with a previous report (Yonezawa et al., 2005).
We then performed a similar cell-to-cell infection assay by
using THP-1 or THP-1 cells treated with PMA, which served as
either donor or target cells; PMA is known to differentiate THP-1
monocytes to macrophages. In both cases, the rVSV-GFP-GP
infection efﬁciency mediated in co-cultured cells was much
greater than was cell-free infection (Fig. 7C and D). Notably, rVSV-
GFP-GP transfer from PMA-treated THP-1 cells to 293FT/Gluc cells
was about 10-fold more efﬁcient than transmission from parental
THP-1 cells to 293FT/Gluc (data not shown), which likely reﬂects
the low infection capability of donor THP-1 cells by rVSV-GFP-GP
as compared to PMA-treated THP-1 cells. However, there was no
signiﬁcant difference between PMA-treated or untreated THP-1
cells when they served as target cells (compare bar 1 and bar 3,
p40.05; Fig. 7E). Similar to the results shown for 293T-to-293FT
transfer, both cell-to-cell infection and cell-free infection of rVSV-
GFP-GP were strongly inhibited by KZ52, LAT-B and CytoD (Fig. 7C
and D).
To conﬁrm the results of cell-to-cell spread infection of rVSV-
GFP-GP between 293T and 293FT cells, we applied a viscous 1%
methylcellulose solution to co-cultured 293T and 293FT/Tomato
cells; in parallel, this solution was also applied to cell-free viral
infection. Previously, methylcellulose has been used to distinguish
between cell-cell and cell-free viral infection (Jin et al., 2009). As
shown in Fig. 7F and G, methylcellulose almost completely blocked
the cell-free infection of rVSV-GFP-GP, yet had no apparent effect on
cell-to-cell infection. Taking all above results together, we conclude
that coculturing monocytes/macrophages and epithelial cells
enhances spread of replication-competent rVSV-GFP-GP in vitro.Discussion
Using retroviral pseudotypes, EBOV VP40-based VLPs, as well
as rVSVs encoding GP, we demonstrate in this work that cell–cell
contact promotes EBOV GP-mediated infection. Interestingly, we
found that the EBOV GP protein alone, even in the absence of the
retroviral Gag-Pol, is sufﬁcient to transfer Tet-off from cell to cell,
and that the key molecules involved in cell-to-cell transfer parallel
that of authentic EBOV infection. We further showed that the
cellular cathepsins B/L and NPC1 are essential for cell-to-cell
transfer to occur. We ruled out the possibility that cell–cell
fusion on the plasma membrane is responsible for the increased
Gluc activity by separately expressing EBOV GP in target cells and
Tet-off in donor cells, with no Gluc activity detected.
Several lines of evidence support the conclusion that cell-to-
cell transfer of Tet-off from donor cells to target cells mediated by
EBOV GP is speciﬁc and not due to experimental artifacts. First, the
increase in Gluc activity is only detected in cells co-expressing
Fig. 7. Cell-to-cell transmission occurs in epithelial cells and macrophages for replication-competent rVSV encoding EBOV GP. (A–D) Cell-to-cell transmission was performed by
co-culturing donor cells (293T, THP-1 or PMA-treated THP-1 cells) infected with appropriate amounts of rVSV-GFP encoding EBOV GP (green) and target 293FT cells that were
pre-labeled with CMTMR (red). The efﬁciency of cell-to-cell transmission was determined by gating the GFP positive cell population in the CMTMR-labeled cells using ﬂow
cytometry. (A) Representative ﬂow cytometry ﬁles show the infection rates of rVSV-GFP-EBOV GP via cell-to-cell transmission or cell-free infection at 2, 6 and 12 h following co-
culture. (B) Summary of the transmission of rVSV-GFP encoding EBOV GP from 293T to 293FT cells in comparison with that of cell-free infection; the effects of KZ52, LAT-B, and
CytoD on these two modes of infection are also shown. (C and D) Transmission of rVSV-GFP encoding EBOV GP from THP-1 cells or PMA-treated THP-1 (macrophages) to 293FT
cells. In all cases, 20 mg/ml of KZ52, 1 mM of LAT-B, or 1 mM of CytoD were used to treat co-cultured cells. Results shown are from at least three independent experiments
performed in duplicate. (E) Transmission of rVSV-GFP encoding EBOV GP from 293FT cells to THP-1 cells or THP-1 cells treated with PMA (macrophages). (F) Effects of
methylcellulose on cell-to-cell transmission or cell-free infection of rVSV-GFP encoding EBOV GP. 293T cells were infected with appropriate amounts of rVSV expressing EBOV GP;
24 h post-infection, the infected 293T cells were co-cultured with 293FT/tdTomato cells at a 1:3 ratio in the presence or absence of 1% methylcellulose. GFP signals in the Tomato-
positive cell populations were analyzed by ﬂow cytometry. For cell-free virus infection, 293FT/tdTomato cells were directly infected with appropriate amounts of rVSV expressing
EBOV GP in the presence or absence of 1% methylcellulose. (G) Representative images showing cell-to-cell transmission or cell-free infection of rVSV-GFP encoding EBOV GP in the
presence or absence of methylcellulose (mock). Note that the rVSV-GFP-GP viral stocks used for cell-free infection here were not from the same donor cells used for cell-to-cell
infection. Images shown were taken after 18–24 h after infection. In all cases, results were from at least three independent experiments. *po0.05; **po0.01; ***po0.001.
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alone. Second, the increased Gluc signal in the culture media of
GP-expressing cells, but not that of VSV-G-expressing cells, is
diminished by KZ52, a broadly neutralizing antibody against EBOV
GP, as well as by 3.47, a small molecule inhibitor that speciﬁcally
blocks EBOV GP from binding to its receptor NPC1. Third, EBOV GP
mutants deﬁcient for NPC1 binding or infection exhibit decreased
activities of cell-to-cell transfer efﬁciency. In addition, we tested
an EBOV GP mutant engineered to harbor a furin-recognizing
sequence in place of the putative cathepsin L cleavage site and
found that this GP exhibits signiﬁcantly increased cell-to-cell
transfer efﬁciency (data not shown). It is noteworthy that other
viral glycoproteins, such as VSV-G and IAV HA, can also efﬁciently
mediate cell-to-cell transfer of Tet-off at neutral pH. However, the
Gluc activities induced by these two viral fusion proteins are
dramatically enhanced by an extracellular low pH pulse, indicating
that cell–cell fusion at the plasma membrane can contribute to
cell-to-cell transfer, although this is not the case for EBOV, nor for
VSV-G and IAV HA, all of which require low pH directly or indir-
ectly for fusion. Because no infectious EBOV virions or virus-like
particles are involved in this very sensitive Tet-off-based cell-to-
cell infection assay, we suggest that this system could be extre-
mely useful for study of highly contagious BL4 agents such as
EBOV and Hanta virus, including screens for potential entry
inhibitors.
What are the possible mechanisms of the enhancement of
EBOV GP-mediated cell-to-cell infection compared to cell-free
infection? One obvious possibility is that cell–cell contact can
increase the local concentrations of retroviral pseudovirions, EBOV
VLPs, and rVSV-GP, resulting in relatively high MOIs that enhanced
infection and spread. In contrast, viral particles in the cell-free
infection system may be relatively unstable, or more susceptible to
inactivation by serum and other culture conditions. Evidence
supporting this scenario is that spinoculation of cell-free virions
produced from donor cells did increase cell-free infection efﬁ-
ciency. Additionally, we provide data showing that exosomes,
which may or may not be concentrated in the cell–cell contact
area, are enriched with EBOV GP, and that inhibition of exosome
release by a chemical inhibitor GW4869 led to decreased Tet-off
transfer from cell to cell. Indeed, exosomes have recently been
shown to play roles in viral cell-to-cell transmission and patho-
genesis, although the underlying mechanism remains murky
(Madison and Okeoma, 2015); more work is needed to dissect the
exact roles of exosomes in EBOV infection. It is formally possible
that different forms of EBOV GP, including full-length GP as well as
secreted GP (sGP), may function through exosomes that modulate
EBOV spread in a VP40-indepenent fashion.
Our study strongly suggests, though does not deﬁnitely prove,
that EBOV GP promotes viral cell-to-cell transmission in addition
to mediating cell-free infection; not surprisingly, both modes of
infection require cathepsin and NPC1. Strong similarities between
cell-to-cell and cell-free infection, including sensitivities to the
neutralizing antibodies, have also been demonstrated for HIV
(Agosto et al., 2014). It is thus possible that EBOV GP may associate
with some cell surface molecules, including TIM-1 and DC-SIGN,
thereby creating a structure known as virological synapse (VS) to
facilitate cell-to-cell transmission. It is also possible that EBOV
particles may travel from donor cell to target cell through nano-
tubular or related structures. Hence, detailed analyses of EBOV
infection using high-resolution live-cell imaging would be infor-
mative to address these possibilities. Ultimately, we will need to
address if authentic live EBOV, or EBOV derived from reverse
genetics systems (Hoenen and Feldmann, 2014b), can spread via
cell–cell contact in humans and animal infections as well as their
implications for viral pathogenesis and antiviral therapy (Qiu et al.,
2014; Warren et al., 2014).Materials and methods
DNA constructs and plasmids
The native full-length EBOV GP construct was originally pro-
vided by Gary Kobinger (National Microbiology Laboratory, Win-
nipeg, Canada). The mucin-deleted EBOV GP (pcDNA- Δmuc-GP)
was originally provided by David Sanders (Purdue University). The
N-terminal FLAG-tagged full length EBOV GP construct (F-GP) was
made by replacing the signal peptide of GP with that of pre-
protrypsin followed by a FLAG sequence (inserted between the
signal peptide and mature GP); this F-GP was subcloned into the
backbone of pCIneo (Promega). The N-terminal FLAG-tagged GP
present in pCIneo-F-GP was subcloned into the mucin-deleted
pcDNA-Δmuc-GP construct, resulting in Δmuc-F-GP, which was
primarily used in this study. All EBOV GP mutants were generated
by overlapping PCR-based mutagenesis using pcDNA-F-Δmuc
construct as the template. All constructs were conﬁrmed by DNA
sequencing.
The pQCXIP-Tet-off construct was provided by Marc Johnson
(University of Missouri) (Janaka et al., 2013). The 3 FLAG-tagged
NPC1 and NPC1 domain C proteins with the cytoplasmic tail
deleted constructs (referred to as NPC1 CT in this work) were from
Kartik Chandran (Albert Einstein College of Medicine) (Miller et al.,
2012). VP40 was provided by Yoshihiro Kawaoka (University of
Wisconsin, Madison), VP40-Blam was provided by Lijun Rong
(University of Illinois, Chicago) and VP40-GFP was provided by
Kartik Chandran. The inﬂuenza HA and NA constructs were offered
by Gary Nabel (Vaccine Research Center, NIH).Cell lines and reagents
293T, 293GP/LAPSN (expressing MLV Gag-Pol and transfer
vector encoding alkaline phosphatase) and HTX (a subclone of
HT1080) have been previously described (Côté et al., 2008). THP-1
cells were obtained from ATCC. The 293FT/Gluc cell line that stably
expresses Gluc was provided by Marc Johnson (Janaka et al., 2013).
The 293FT/Gluc cell lines stably expressing NPC1or NPC1 CT or
TIM-1 were generated by transducing 293FT/Gluc cells with pBabe
(for NPC1 and NPC1 CT) or with a pQCXIP (for TIM-1) retroviral
vector expressing the individual proteins, followed by puromycin
selection (Sigma, 2 mg/ml). All cells were grown in Dulbecco's
modiﬁed Eagle's (DMEM) medium, supplemented with 0.5%
penicillin/streptomycin plus 10% fetal bovine serum (FBS).
The human KZ52 antibody was provided by Dennis Burton and
Erica Saphire (The Scripps Research Institute) (Lee et al., 2008;
Parren et al., 2002). The rabbit antibody against EBOV GP1 and
3.47 were obtained from James Cunningham (Harvard Medical
School) (Côté et al., 2011). The anti-NPC1 antibody was purchased
from Abcam (Cambridge, MA). The anti-TIM-1 antibody was pur-
chased from R&D Systems. The anti-CD63 antibody was purchased
from Invitrogen (Carlsbad, CA). The anti-MLV Gag antibody was
puriﬁed from R187 hybrioma cell line (ATCC). Leupeptin, E64d,
CA074, and cathepsin L inhibitor III (Z-Phe-Tyr(t-Bu)-diazo-
methylketone, also known as Z-FY(t-Bu)-DMK) were all purchased
from EMD Millipore (Billerica, MA). Ammonium chloride (NH4Cl),
12-O-Tetradecanoylphorbol 13-acetate (PMA), methylcellulose,
GW4869, shRNA lentiviral vectors targeting NPC1, anti-FLAG
antibody, anti-β-actin antibody, and secondary anti-mouse
immunoglobulin G conjugated to FITC or HRP were purchased
from Sigma (St Louis, MO). The Gaussia luciferase activity was
measured by following the manufacturer’s instructions (Promega,
Madison, WI) with minor modiﬁcations.
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For the retroviral vector-based system, 293T cells were seeded
onto six-well plates and transfected with 1 μg pQCXIP-Tet-off
vector, 1 μg MLV Gag-Pol and 0.5 μg of plasmids encoding EBOV
GP, IAV HA or VSV-G. Alternatively, MLV Gag-Pol was omitted in
the transfection. The next day, 2105 of the transfected 293T
donor cells were thoroughly washed and trypsinized in order to
remove bound virus and residual plasmid DNA, followed by co-
culturing with 4105 293FT/Gluc target cells or derivatives in 24-
well plates for 24–48 h. Inhibitors were added during co-culture
unless otherwise speciﬁed. For Transwell settings, cell-to-cell
infections were determined by co-culturing donor and target
cells on the bottom (without insert) and cell-free infection was
measured by seeding donor cells on the top well and target cells
mixed with the same number of untransfected donor cells on the
bottom. Approximately 2 ml of co-cultured media were assayed for
Gluc activity in 10 ml buffer containing 10 μM coelenterazine in
0.1 M Tris, pH 7.4 and 0.3 M sodium ascorbate. In all experiments,
293T donor cells transfected with pQCXIP-Tet-off alone were co-
cultured with target cells to serve as background control.
For the VP40-based VLP assay, we transfected 293T cells with
VP40-Blam or VP40-GFP in the presence or absence of EBOV GP.
The transfected cells were co-cultured with 293FT/tdTomato cells,
and cell-to-cell transfer efﬁciency was determined by measuring
virus uptake using a Blam-based virion-fusion assay (Tscherne and
Garcia-Sastre, 2011) or by detecting a GFP signal using ﬂow cyto-
metry. Inhibitors were added during co-culture if applicable.
For the rVSV-based assay, 293T, THP-1, or PMA-treated THP-1
cells were infected with appropriate amounts of rVSV-GFP
expressing EBOV GP or VSV-G (kindly provided by Kartik Chan-
dran), and the infected cells were co-cultured with CMTMR-
labeled 293FT, THP-1, or THP-1 cells treated with PMA, or co-
cultured with 293FT/tdTomato cells (red). If desirable, 1%
methylcellulose was laid on top of co-cultured cells. Cell-to-cell
infection was measured by ﬂow cytometry by measuring the GFP
signal in red-cell populations or visualized by ﬂuorescence
microscope. Inhibitors were applied during co-cultured as needed.
Cell-free infection
When counting donor cells for cell-to-cell infection, an
equivalent number (2105) of transfected or infected donor cells
were seeded onto a new 6-well plate and cultured for the same
time period as the duration of cell-to-cell infection. The total
volumes of supernatants were harvested, and used to infect target
cells that were mixed with un-transfected 293T cells; this ensured
that cell numbers used for cell-to-cell and cell-free assays were
absolutely comparable. If needed, spinoculation or 1% methylcel-
lulose was applied during infection. The cell-free infectivity was
determined at 24–48 h for Gluc activity or 2–12 h for GFP detec-
tion (rVSV-GFP and VP40-GFP) after infection. For experiments
involving inhibitors or the KZ52 antibody, cells were pre-treated
with appropriate concentrations of these agents for 2 h and sub-
sequently infected with viruses in the presence of the agents
throughout infection. In some cases, 293GP/LAPSN packaging cells
were used to produce MLV pseudovirions bearing EBOV GP and
HTX cells were used as target cells for infection; the viral titer was
determined by alkaline phosphatase (AP) staining.
Isolation and puriﬁcation of exosomes
Isolation of exosomes was carried out by using a referenced
protocol, with minor modiﬁcations (Thery et al., 2006). Brieﬂy,
293T donor cells were co-transfected, using a calcium phosphate
method, with pQCXIP-Tet-off vector and a plasmid encodingEBOV GP. The supernatants of transfected cells were harvested
24–48 h post-transfection. Supernatants containing exosomes
were clariﬁed by centrifugation for 10 min at 300g and 4 °C to
remove cells, followed by centrifugation for 10 min at 2000g and
4 °C to remove cell debris. Supernatants containing the exosomes
were further clariﬁed by ultracentrifugation for 30 min at 10,000g
at 4 °C. Exosomes were then concentrated by ultracentrifugation
for 70 min at 100,000g at 4 °C, and re-suspended in PBS buffer.
Contaminating proteins in exosome suspensions were removed by
an additional ultracentrifugation for 70 min at 100,000g at 4 °C.
Puriﬁed exosomes were boiled in a sodium dodecyl sulfate (SDS)
sample buffer for 10 min before loading to 10% SDS-PAGE elec-
trophoresis and Western blotting. An anti-FLAG was used to detect
EBOV GP and anti-CD63.
Western blotting
Cells were lysed in lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1 mM EDTA and 1% Triton) containing freshly added PMSF
and a protease inhibitor cocktail (Sigma) for 20 min on ice. The
lysates were clariﬁed by centrifugation at 13,000g and 4 °C for
10 min, followed by boiling for 10 min in SDS sample buffer. Cell
lysates were subjected to 7.5% or 10% SDS-PAGE electrophoresis,
followed by transfer onto polyvinylidene diﬂuoride membranes.
Western blotting was performed by using speciﬁc primary anti-
bodies, followed by appropriate secondary antibodies conjugated
to horseradish peroxidase. The signals were detected by the che-
miluminescence image analyzer LAS3000 (GE Healthcare Bio-Sci-
ences, Pittsburgh, PA).
Flow cytometry
Cells were detached from dishes by adding PBS plus 5 mM
EDTA, and re-suspended in PBS containing 2% FBS. Cells were then
incubated with mouse anti-FLAG antibody on ice for 1 h, washed
3 times with cold PBS containing 2% FBS, and incubated with FITC
conjugated anti-mouse IgG antibody for an additional 45 min.
Cells were ﬁxed and analyzed by ﬂow cytometry.
Immunoﬂuorescence staining and 3D de-convolution microscopy
293FT/Gluc cells stably expressing NPC1, NPC1 CT or TIM-1
were ﬁxed with 4% paraformaldehyde, and permeabilized with
0.25% Triton X-100 for 10 min. Cells were blocked with 5% BSA,
and stained with anti-FLAG antibody for 1 h. After 3 washes with
PBS, cells were incubated with anti-mouse FITC for 1 h. Cells were
stained with DAPI and Z-stack images were collected using a Leica
DMI6000 B inverted deconvolution microscope with a 60 oil
immersion lens.
Statistical analysis
One-way ANOVA analysis of variance, with Dunnett multiple
comparison methods, was used to perform all statistical tests.
Unless otherwise speciﬁed, results from 3 to 6 independent
experiments were used for the analysis.Acknowledgments
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